Table 4.
Alirocumab (n = 92) | Placebo (n = 48) | |
---|---|---|
Non–HDL-C <100 mg/dL | 83 (90.2) | 10 (20.8) |
LDL-C <70 mg/dL | 80 (87.0) | 8 (16.7) |
LDL-C <70 mg/dL and non–HDL-C <100 mg/dL | 79 (85.9) | 6 (12.5) |
Data reported as n (%).
Alirocumab (n = 92) | Placebo (n = 48) | |
---|---|---|
Non–HDL-C <100 mg/dL | 83 (90.2) | 10 (20.8) |
LDL-C <70 mg/dL | 80 (87.0) | 8 (16.7) |
LDL-C <70 mg/dL and non–HDL-C <100 mg/dL | 79 (85.9) | 6 (12.5) |
Data reported as n (%).